Romiplostim was safe and effective at an initial dosage of 20 μg/kg per week, with rapid responses in patients with refractory aplastic anemia who experienced treatment failure with immunosuppressive therapy and multiple oral thrombopoietin receptor agonists. The gene discussed is MPL; the disease is aplastic anemia.